# Carcinoma nasofaríngeo

> Página oficial: https://raras.org/doenca/carcinoma-nasofaringeo
> Fonte: Raras.org — Banco de Dados de Doenças Raras em Português (CC BY-NC-SA 4.0)
> Última atualização: 2026-05-08

## Identificadores

- **ORPHA**: 150 — https://www.orpha.net/en/disease/detail/150
- **CID-10**: C11.0
- **OMIM**: none — https://omim.org/entry/none

## Descrição clínica

Carcinoma que surge do epitélio nasofaríngeo. Inclui os seguintes tipos: carcinoma espinocelular queratinizante, carcinoma não queratinizante (diferenciado e indiferenciado), carcinoma espinocelular basaloide e adenocarcinoma papilar.

## Epidemiologia e herança

- **Prevalência**: Unknown
- **Padrão de herança**: Multigenic/multifactorial, Not applicable

## Genes associados (1)

- **NFKBIA** — NF-kappa-B inhibitor alpha [Disease-causing somatic mutation(s) in]
  - Função: Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localization signals (PubMed:1493333, PubMed:3665180

## Medicamentos em desenvolvimento (5)

- CAPECITABINE — Fase Phase 3 (Thymidylate synthase inhibitor)
- FLUOROURACIL — Fase Phase 3 (Thymidylate synthase inhibitor)
- NIMOTUZUMAB — Fase Phase 3 (Epidermal growth factor receptor erbB1 inhibitor)
- RIVOCERANIB — Fase Phase 3 (Vascular endothelial growth factor receptor 2 inhibitor)
- DOCETAXEL — Fase Phase 3 (Tubulin inhibitor)
- Fonte: https://platform.opentargets.org/disease/MONDO_0015459

## Ensaios clínicos ativos (31)

- **NCT06064097** [RECRUITING]: A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) — https://clinicaltrials.gov/study/NCT06064097
- **NCT05904080** [RECRUITING]: Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer — https://clinicaltrials.gov/study/NCT05904080
- **NCT06980038** [RECRUITING]: Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer — https://clinicaltrials.gov/study/NCT06980038
- **NCT03010150** [RECRUITING]: Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer — https://clinicaltrials.gov/study/NCT03010150
- **NCT06093061** [RECRUITING]: Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma — https://clinicaltrials.gov/study/NCT06093061
- **NCT06029270** [RECRUITING]: Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer — https://clinicaltrials.gov/study/NCT06029270
- **NCT06532279** [RECRUITING]: Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer — https://clinicaltrials.gov/study/NCT06532279
- **NCT05587543** [RECRUITING]: Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma — https://clinicaltrials.gov/study/NCT05587543
- **NCT05941741** [RECRUITING]: IC Plus Low-dose Radiation Plus Cadonilimab in LANPC — https://clinicaltrials.gov/study/NCT05941741
- **NCT07459296** [RECRUITING]: Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC — https://clinicaltrials.gov/study/NCT07459296

## Importante

O Raras **não diagnostica e não prescreve**. Esta página é educativa e informativa.
Pacientes devem consultar profissionais de saúde qualificados para decisões clínicas.

---

**Citação sugerida**: Raras.org — Carcinoma nasofaríngeo. Disponível em: https://raras.org/doenca/carcinoma-nasofaringeo
**Formato HTML**: https://raras.org/doenca/carcinoma-nasofaringeo
**Formato RDF/Turtle**: https://raras.org/api/rdf?orpha=150